C4 Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Stockholder’s Equity
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · Accumulated Deficit · TotalStockholders' Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2023 | 60,467,188 | $6 | $774,618 | (127) | $(528,383) | $246,114 |
| Issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 5,567,928 | 1 | 19,999 | — | — | 20,000 |
| Issuance of common stock pursuant to the at-the-market equity program, net | 2,500,601 | — | 14,089 | — | — | 14,089 |
| Issuance of common stock upon exercise of stock options | 80,936 | — | 519 | — | — | 519 |
| Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 121,516 | — | (109) | — | — | (109) |
| Issuance of common stock under 2020 ESPP | 34,902 | — | 84 | — | — | 84 |
| Stock-based compensation | — | — | 6,215 | — | — | 6,215 |
| Change in unrealized loss, net on marketable securities | — | — | — | (253) | — | (253) |
| Net loss | — | — | — | — | (28,361) | (28,361) |
| Other | 5,520 | — | (16) | — | — | (16) |
| Balance as of March 31, 2024 | 68,778,591 | $7 | $815,399 | $(380) | $(556,744) | $258,282 |
| Exercise of stock options and release of stock units | 32,607 | — | 135 | — | — | 135 |
| Stock-based compensation | — | — | 6,381 | — | — | 6,381 |
| Change in unrealized loss, net on marketable securities | — | — | — | (60) | — | (60) |
| Net loss | — | — | — | — | (17,716) | (17,716) |
| Other | 4,444 | — | 36 | — | — | 36 |
| Balance as of June 30, 2024 | 68,815,642 | $7 | $821,951 | $(440) | $(574,460) | $247,058 |
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders'Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 48,966,216 | $5 | $689,256 | $(4,137) | $(395,890) | $289,234 |
| Issuance of common stock upon exercise of stock options | 11,759 | — | 56 | — | — | 56 |
| Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding | 48,730 | — | (94) | — | — | (94) |
| Issuance of common stock under 2020 ESPP | 20,748 | — | 104 | — | — | 104 |
| Stock-based compensation | — | — | 6,251 | — | — | 6,251 |
| Change in unrealized loss, net on marketable securities | — | — | — | 1,667 | — | 1,667 |
| Net loss | — | — | — | — | (34,780) | (34,780) |
| Other | 5,056 | — | 32 | — | — | 32 |
| Balance as of March 31, 2023 | 49,052,509 | $5 | $695,605 | $(2,470) | $(430,670) | $262,470 |
| Exercise of stock options and release of stock units | 1,337 | — | 2 | — | — | 2 |
| Stock-based compensation | — | — | 6,425 | — | — | 6,425 |
| Change in unrealized loss, net on marketable securities | — | — | — | 696 | — | 696 |
| Net loss | — | — | — | — | (35,922) | (35,922) |
| Other | 11,252 | — | 36 | — | — | 36 |
| Balance as of June 30, 2023 | 49,065,098 | $5 | $702,068 | $(1,774) | $(466,592) | $233,707 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.